Objectives MF59-adjuvanted standard-dose and nonadjuvanted high-dose seasonal
influenza vaccines have been developed to protect the elderly at high risk of severe …

Background A number of enhanced influenza vaccines have been developed for use in
older adults, including high-dose, MF59-adjuvanted, and intradermal vaccines. Methods We …

Background In the elderly, traditional influenza inactivated vaccines are often only modestly
immunogenic, owing to immunosenescence. Given that adjuvantation is a means of …

Background Standard‐dose seasonal influenza vaccines often produce modest
immunogenic responses in adults≥ 65 years old. MF59 is intended to elicit a greater …

Introduction Older adults are prioritized for influenza vaccination but also have lowered
antibody responses to the vaccine. Higher-doses of influenza antigen may increase immune …

Background: The elderly are at a higher risk of morbidity and mortality associated with
influenza infection than younger adults, but get less protection from conventional …

Aim Adjuvanted influenza vaccines can overcome the poor antibody response of
conventional non-adjuvanted vaccines in the elderly. We evaluated the immunogenicity …

Background Influenza-associated morbidity and mortality has not decreased in the last
decade, despite increased receipt of vaccine. To improve the immunogenicity of influenza …

Background This study aimed to estimate influenza vaccine effectiveness (VE) in preventing
influenza-related deaths and hospitalizations in the elderly population. Methods We …

This updated systematic review and meta-analysis of randomized and observational studies
published up to April 2023 assessed the relative performance of high-dose inactivated …